Pricing Log in Create free account
Friday 6 November 2026 Export ICLR’s income statement to Excel — free account

ICON PLC

ICLR Healthcare Diagnostics & Research

ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.

Revenue
−2.86%
EPS
+143.2%
Free cash flow
−8.01%
Total debt
−0.86%

Quarter to September 2026, against a year earlier

201.62 1.49 −0.73%
Market cap
$15.1B
P/E
34.5×
Fwd P/E
34.6×
Dividend yield
—
F-score
6/9
Altman Z
2.01
Beneish M
−2.62
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

ICON PLC (ICLR) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, ICON PLC (ICLR) trades at a EV/EBITDA of 17.9×. Over the past ten years it has ranged from 9.3× (May 2025) to 54.7× (December 2021); the current reading is higher than 66% of that period. That is below the Diagnostics & Research industry median of 23.4× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 20.6× 55.52%
FY2024 13.3× (22.62%)
FY2023 17.2× 16.19%
FY2022 14.8× (59.80%)
FY2021 36.7× 70.83%
FY2020 21.5× 23.63%
FY2019 17.4× 5.54%
FY2018 16.5× 0.74%
FY2017 16.4× 32.98%
FY2016 12.3× (17.75%)

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 15.6× (34.13%)
Jun 2026 23.7× 63.73%
Mar 2026 14.5× (29.85%)
Dec 2025 20.6× 7.20%
43 more quarters

Against its own ten years

Low 9.3× High 54.7×
Ten-year median 16.8×
Current reading's percentile 66

EV/EBITDA against peers

Company EV/EBITDA
GH Guardant Health, Inc. compare n/m
DGX Quest Diagnostics Incorporated compare 14.2×
LH Labcorp Holdings Inc. compare 15.6×
QGEN QIAGEN N.V. compare 17.4×
ICLR ICON PLC 17.9×
RVTY Revvity Inc. compare 25.1×
ILMN Illumina, Inc. compare 26.4×
MEDP Medpace Holdings, Inc. compare 27.0×
CRL Charles River Laboratories International, Inc. compare 31.2×
Diagnostics & Research industry median 23.4×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ICLR